Bio-Rad Laboratories, Inc. · NYSE:BIO
Bio-Rad Laboratories — Jefferies 2019 Healthcare Conference
26 slides from Bio-Rad Laboratories's conference presentation, 2019

Slide 1: Bio-Rad Laboratories, Inc. Jefferies 2019 Healthcare Conference
Bio-Rad Laboratories, Inc. Jefferies 2019 Healthcare Conference

Slide 2: Forward-Looking Statements
Forward-Looking Statements Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding our investment in high growth emerging markets and development of new prod

Slide 3: Bio-Rad Today
Bio-Rad Today Continuous 65+ Years Strong Innovation A History of Contribution Performance Key Competencies $2.2B+ Annual Sales Fueling Ongoing Growth Complementary 8,300+ Employees Worldwide Business Mix Leveraging Across the Company Advance discovery. Improve lives.

Slide 4: Bio-Rad Global Profile
Bio-Rad Global Profile Applied 3% BioPharma Asia 11% EMEA 21% Hospital Labs 35% 38% Academic 23% Customers Geography Products Transfusion Labs Reference Labs Americas 13% 12% 44% Diversified Customer Base Worldwide Presence Broad Product Base Advance discovery. Improve lives.

Slide 5: A History of Innovation
A History of Innovation 2012 1982: First commercial Bio-Rad launches the 1967: Bio-Rad launches first T-4 test for Hemoglobin A1c droplet digital PCR by column test revolutionizing system Thyroid testing 2006: Place first multiplex immunoassay system BioPlex 2200 2000 Launched the first 4- color rea

Slide 6: Leadership Positions
Leadership Positions DNA amplification Autoimmune Bio-Chromatography Diabetes Market Focus Infectious Disease Electrophoresis Blood Typing Gel image Quality Control Protein Assay Digital Biology Advance discovery. Improve lives.

Slide 7: Bio-Rad is Well-Positioned in New Focus on Lab to Clinic Solutions
Bio-Rad is Well-Positioned in New Focus on Lab to Clinic Solutions Translational Research Continuum Discovery Development Production Treatment & follow up • Basic disease • Target validation • Clinical studies • Treatment mechanism • Lead development • Regulatory planning and research of a therapy a

Slide 8: Life Science Profile
Life Science Profile Highlights Market Size: $45B–50B Market Growth 4% CAGR Addressable Market: $8–9B Asia 26% Americas Research Applied Markets 43% Revenue Consumables 63% 7% Geography 48% Customer Products Segments EMEA BioPharma 31% Instruments/ Apparatus 30% 52% Source: Bio-Rad Internal 8

Slide 9: Life Science Solutions
Life Science Solutions Genotyping & Gene Gene Transfer & Modulation Protein Purification Expression (chromatography) (PCR & qPCR) Protein Expression (multi-analyte detection) Multi-omics Solutions Digital Biology (Droplet Digital PCR, ddSeq) Protein Quantification (western blotting) Cellular Imaging

Slide 10: Cell Biology
Cell Biology New Entrant in Growing Market Flow Cytometry Cell Sorters and Analyzers Flow Cytometry Cell Imagers and Counters Antibodies TC20 Automated Flow Cytometry Reagents & Assays Cell Counter Flow Cytometry Antibodies S3e Cell Sorter ZOE Fluorescent Cell Imager ZE5 Cell Analyzer 10 Adv

Slide 11: Digital Biology
Digital Biology Leadership Position • ddPCR technology • Broad IP portfolio • Broad application from research to therapeutics • Rapid development of new applications Advance discovery. Improve lives.

Slide 12: Clinical Diagnostics Profile
Clinical Diagnostics Profile Highlights Market Size: $55-60B Asia Addressable Market: $5.5B 19% Market Growth ~ 5% EMEA 39% Instruments Transfusion Revenue 25% Laboratory Geography 18% Customer Products Segments Hospital Americas Laboratory 42% Reference 61% Laboratory Reagents 21% 75% Source:

Slide 13: Clinical Diagnostics
Clinical Diagnostics Diagnostic Testing Protecting the Quality and Monitoring Blood Supply Assurance Diabetes Blood Typing Quality Controls Infectious Disease Blood Virus Screening Quality Assessments Autoimmune HIV Confirmation Testing Data Management Transfusion Compatibility 1

Slide 14: Blood Typing
Blood Typing Highlights Bio-Rad #2 in Market 3,000+ Automated Systems Placed Gel Cards Unrivalled Results Management Broadest portfolio for safe transfusions Tango infinity Geographic Expansion IH-1000 and IH-500 FDA Approvals IH-Com and Manual Systems Approval Growing Demand in Emergi

Slide 15: Portfolio Expansion
Portfolio Expansion Near Term Focus • Core Market Enhancement • Microbiome • Point of Care • Non-Invasive Prenatal Testing Advance discovery. Improve lives.

Slide 16: The Importance Of Clinical Diagnostics In Healthcare
The Importance Of Clinical Diagnostics In Healthcare Targeted Disease Prevention Early Disease Detection Accelerated Diagnostics Targeted Therapy Earlier detection saves lives Improved • Lowers total costs Outcomes • Reduces risks • Increases satisfaction • Improves treatment efficiency 16 Advance d

Slide 17: Diabetes
Diabetes Diabetes is an accelerating global problem. 17 Advance discovery. Improve lives.

Slide 18: Bio-Rad Pioneered HbA1c Testing
Bio-Rad Pioneered HbA1c Testing Bio-Rad provides HbA1c testing solutions for all segments, leading to better outcomes for patients with diabetes. Small Labs / Medium Labs Large Labs Clinics D-10 VARIANT II D-100 18 Advance discovery. Improve lives.

Slide 19: Cancer
Cancer The global cancer burden continues to rise, with 18 million new cases and over 9 million deaths in 2018. Early Detection Is Key To Survival 19 * Cancer Research UK Advance discovery. Improve lives.

Slide 20: Bio-Rad Is Pioneering Digital PCR In Liquid Biopsy
Bio-Rad Is Pioneering Digital PCR In Liquid Biopsy Bio-Rad products enable monitoring of a patient’s response to targeted therapy. Systems Consumables Menu Droplet digital PCR For customers developing Large portfolio of assays platforms and validating tests 20 Advance discovery. Improve lives.

Slide 21: Translational Discovery to Diagnostics
Translational Discovery to Diagnostics Discovery Production Basic disease mechanism research Clinical studies Pathway research Regulatory Target identification Translational Drug and/or diagnostics manufacturing and Medicine commercialization Development Therapies Target validation T

Slide 22: Operational Transformation
Operational Transformation Building a Scalable Model Advance discovery. Improve lives.

Slide 23: The Opportunity
The Opportunity Leverage Rationalize Manage ERP Investment Global Footprint Procurement Increase visibility Consolidate distribution Centralized Procurement centers Global price concessions Optimize inventory levels Close redundant Targeted reduction in Improve service commercial sit

Slide 24: The Path Forward
The Path Forward Geographic Expansion Optimized Supply Chain New Products Reduced ERP Spend New Markets Driving Expanding Shared Services Revenue EBITDA Operating Leverage Growth Margins Increased Cash Flow Creating Accelerating Higher Profitability Shareholder Free Cash Discipli

Slide 25: Summary – Closing Remarks
Summary – Closing Remarks Investments at an inflection point Building on our market and product leadership Increased focus on acquisition opportunities Leveraging our new organization, operating model and systems to drive value Advance discovery. Improve lives.

Slide 26: Bio-Rad Laboratories, Inc. Jefferies 2019 Healthcare Conference
Bio-Rad Laboratories, Inc. Jefferies 2019 Healthcare Conference
Source: Internet Archive copy of bio-rad.com
More decks from Bio-Rad Laboratories, Inc.
Q3 2026 Earnings Presentation16 slides · Nov 4, 2026
Q2 2026 Earnings Presentation18 slides · Aug 4, 2026
Q1 2026 Earnings Presentation18 slides · Apr 30, 2026
Q4 2025 Earnings Presentation26 slides · Feb 12, 2026
Q3 2025 Earnings Presentation17 slides · Oct 29, 2025
Bio-Rad's Droplet Digital PCR Webinar (August 2025)18 slides · Aug 26, 2025